Table S1.
Characteristics of the study patient population, overall and by countrya
| Characteristica | Total (n = 713) |
Germany (n = 344) |
Spain (n = 252) |
UK (n = 117) |
P | ||||
|---|---|---|---|---|---|---|---|---|---|
| n | n | n | n | ||||||
| Age, mean (SD) years | 713 | 65.5 (11.0) | 344 | 64.8 (11.1) | 252 | 66.5 (11.1) | 117 | 65.1 (10.4) | NS |
| 36–55 years | 146 (20.5) | 71 (20.6) | 51 (20.2) | 24 (20.5) | |||||
| 56–75 years | 428 (60.0) | 212 (61.6) | 147 (58.3) | 69 (59.0) | |||||
| 76–85 years | 123 (17.3) | 54 (15.7) | 46 (18.3) | 23 (19.7) | |||||
| >85 years | 16 (2.2) | 7 (2.0) | 8 (3.2) | 1 (0.9) | |||||
| Sex, female | 712 | 427 (59.9) | 344 | 200 (58.1) | 251 | 169 (67.3) | 117 | 58 (49.6) | 0.01 |
| Race, white | 713 | 611 (85.7) | 344 | 337 (98.0) | 252 | 177 (70.2) | 117 | 97 (82.9) | <0.001 |
| Spanish/Hispanic | 66 (9.3) | 1 (0.3) | 64 (25.4) | 1 (0.9) | |||||
| Other | 36 (5.0) | 6 (1.7) | 11 (4.4) | 19 (16.2) | |||||
| Employed | 707 | 170 (23.8) | 340 | 91 (26.8) | 251 | 48 (19.1) | 116 | 31 (26.7) | NS |
| Smoker | 692 | 164 (23.0) | 336 | 84 (25.0) | 242 | 61 (26.4) | 114 | 19 (16.7) | NS |
| BMI, mean (SD) | 701 | 27.7 (4.7) | 343 | 28.3 (5.2) | 249 | 27.3 (3.6) | 109 | 26.4 (4.7) | <0.001 |
| Obese (BMI ≥ 30) | 170 (24.3) | 99 (28.9) | 52 (20.9) | 19 (17.4) | |||||
| Concomitant condition | |||||||||
| GI condition | 713 | 171 (24.0) | 344 | 67 (19.5) | 252 | 78 (31.0) | 117 | 26 (22.2) | 0.005 |
| History of CV disease | 713 | 404 (56.7) | 344 | 203 (59.0) | 252 | 156 (61.9) | 117 | 45 (38.5) | <0.001 |
| Hypertension | 404 | 333 (82.4) | 203 | 173 (85.2) | 156 | 121 (77.6) | 45 | 39 (86.7) | NS |
| Depression/anxiety | 284 | 78 (27.5) | 122 | 25 (20.5) | 124 | 43 (34.7) | 38 | 10 (26.3) | 0.04 |
| Other medication | 713 | 344 | 252 | 117 | |||||
| Gastroprotective agent | 335 (47.0) | 111 (32.3) | 184 (73.0) | 40 (34.2) | <0.001 | ||||
| Cardiovascular agent | 375 (52.6) | 182 (52.9) | 138 (54.8) | 55 (47.0) | NS | ||||
| Lipid-lowering agent | 95 (13.3) | 50 (14.5) | 39 (15.5) | 6 (5.1) | 0.02 | ||||
| OA severity,b mild | 705 | 214 (30.0) | 342 | 99 (28.9) | 247 | 77 (31.2) | 116 | 38 (32.8) | <0.001 |
| Moderate | 389 (54.6) | 170 (49.7) | 148 (59.9) | 71 (61.2) | |||||
| Severe | 102 (14.3) | 73 (21.3) | 22 (8.9) | 7 (6.0) | |||||
| Current need for analgesiab | |||||||||
| Mean (SD) | 665 | 4.2 (2.1) | 339 | 3.8 (2.1) | 210 | 4.6 (2.1) | 116 | 4.6 (2.0) | <0.001 |
| 0–2.9 (none) | 665 | 174 (24.4) | 339 | 112 (33.0) | 210 | 39 (18.6) | 116 | 23 (19.8) | <0.001 |
| 3–3.9 | 110 (15.4) | 62 (18.3) | 30 (14.3) | 18 (15.5) | |||||
| 4–5.9 | 190 (26.7) | 93 (27.4) | 61 (29.0) | 36 (31.0) | |||||
| 6–7.9 | 163 (22.9) | 61 (18.0) | 71 (33.8) | 31 (26.7) | |||||
| 8–10 (strongest need) | 28 (3.9) | 11 (3.2) | 9 (4.3) | 8 (6.9) | |||||
| Osteoarthritis, knee | 713 | 472 (66.2) | 344 | 226 (65.7) | 252 | 175 (69.4) | 117 | 71 (60.9) | NS |
| EQ-5D, mean (SD)c | 713 | 0.59 (0.28) | 344 | 0.61 (0.27) | 252 | 0.55 (0.30) | 117 | 0.61 (0.28) | <0.001 |
| HAQ, mean (SD)c | 713 | 1.32 (0.68) | 344 | 1.26 (0.68) | 252 | 1.37 (0.63) | 117 | 1.37 (0.77) | <0.001 |
| 0.0–0.9 | 713 | 245 (35.9) | 344 | 132 (39.4) | 252 | 69 (29.1) | 117 | 44 (39.6) | 0.02 |
| 1.0–1.9 | 322 (47.1) | 148 (44.2) | 132 (55.7) | 42 (37.8) | |||||
| 2.0–2.9 | 114 (16.7) | 53 (15.8) | 36 (15.2) | 25 (22.5) | |||||
| 3.0 | 2 (0.3) | 2 (0.6) | 0 (0.0) | 0 (0.0) | |||||
| WOMAC, mean (SD)c | 519 | 29.1 (17.2) | 241 | 29.6 (16.5) | 190 | 27.7 (16.5) | 88 | 30.3 (19.5) | NS |
| Pain | 552 | 5.7 (3.7) | 263 | 5.6 (3.4) | 196 | 5.7 (3.6) | 93 | 5.9 (20.0) | NS |
| Stiffness | 531 | 2.5 (1.7) | 248 | 2.4 (1.7) | 192 | 2.6 (1.6) | 91 | 2.8 (1.7) | NS |
| Physical function | 681 | 16.1 (4.2) | 322 | 16.4 (14.4) | 245 | 15.5 (13.7) | 114 | 16.6 (15.0) | NS |
Notes: P-value calculated using the Chi-squared test for categorical values and t-test for continuous variables;
values are number (%) of patients unless otherwise indicated;
physician assessment;
patient self-assessment.
Abbreviations: BMI, body mass index; CV, cardiovascular condition; EQ-5D, EuroQol health-related quality of life (score range: zero [dead] to one [perfect health]); GI, gastrointestinal; HAQ, Health Assessment Questionnaire (scale: zero [no disability] to three [complete disability]); OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities OA Index (score range [zero is best]: pain zero to 20; stiffness zero to eight; physical function zero to 68); NS, not statistically significant.